carmel pharma, inc.

Carmel Pharma's sole focus is on the quality of life of those people who prepare, administer and dispose of hazardous drugs. With dedicated resources toward this effort, this means our customers will receive unparalleled service and clinical support.

Carmel Pharma was founded in 1994 and is headquartered in Mölndal, Sweden. These headquarters also house the manufacturing facility for the PhaSeal System, the only clinically proven closed-system drug transfer device that prevents hazardous drug interaction with your environment. Carmel Pharma has been active on the Swedish market ever since, and as a result, PhaSeal is now being used in the majority of Swedish hospitals, as well as facilities across Europe and Asia.

In October of 1999, Carmel Pharma entered the U.S. market by forming Carmel Pharma, Inc. and began distributing the PhaSeal System in the U.S. during 2000.

From 2003 through 2005 PhaSeal was distributed exclusively by an independent distributor. During this period Carmel Pharma, Inc. had minimal business activity but did retain its corporate status.

Effective January 1, 2006 Carmel Pharma, Inc. resumed operations and is now the exclusive distributor of PhaSeal in the U.S. Today over 400 U.S. hospitals, including a number of major cancer centers, such as MD Anderson, Huntsman Cancer Institute, UCSF, and Texas Children’s, use PhaSeal® on a routine basis to ensure their safe handling of hazardous drugs.

Carmel Pharma has nearly 200 shareholders, including Investor Investment Novare Ltd and 3i Nordic.